These may include selective IgG increase, the presence of SLA, severe interface hepatitis with abundant plasma cells for AIH, and definite NASH findings on histology, IgA increase, and prominent metabolic comorbidities for NASH. Here, CD79A is linked to metabolic dysfunction-associated steatohepatitis.